Month: March 2020

HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will present at the Life Sciences Investor Forum being held online at LifeSciencesInvestorForum.com on March 26th.Details of the presentations are below:This will be an interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join on the day of the conference, an archived webcast will also be made available after the event.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.Learn more about...

Burleson, Texas, March 24, 2020 (GLOBE NEWSWIRE) — Muscle Maker Grill (NASDAQ: GRIL) We want to provide a brief update on the current operating environment in response to the ongoing COVID-19 pandemic. While this is proving to be a difficult operating environment across all industry sectors, we view the role of the food industry as crucial, and we remain committed to ramping up operations to continue to serve Americans during this difficult time. Not only are we continuing to serve our guests, from our corporate restaurants and existing franchise model, but also to maintaining an eye on the future, so that we can be prepared for any shifts in the marketplace. We believe our recent announcements regarding Fort Bragg and the 10 location commitment for the delivery-only kitchens provides a clear indication of the non-traditional development...

VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) — Balmoral Resources Ltd. (“Balmoral” or the “Company”) (TSX: BAR; OTCQX: BALMF) announced today, following the orders of the Governments of Quebec and Ontario in response to the COVID-19 pandemic, that it has, effective immediately, suspended until further notice its exploration activities in both provinces.Balmoral’s head office in Vancouver was closed in response to the concerns around COVID-19 on March 12, 2020, with all staff requested to work remotely since that time. To date Balmoral, and Wallbridge Mining Company Limited (“Wallbridge”) with whom Balmoral shares the Fenelon exploration camp in Quebec, have reported no suspected or confirmed cases of COVID-19. The parties have had in place COVID-19 protocols to protect the workforce currently in camp.“The health...

NEW YORK and TORONTO, March 24, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), the leader in augmented reality for eCommerce and AR learning applications, is pleased to announce that it has integrated Zoom (NYSE: ZM) into Jolokia’s Inferno platform extending the capabilities of Zoom meetings out to 100,000 people concurrently with real-time Q&A Plus immersive AR creating a one of a kind new platform. NexTech has a binding LOI to acquire remote video training, live streaming software company Jolokia; whose blue-chip customers include Merck, Toyota Viacom CBS, Polycom and others.What the Inferno – Zoom meetings integration meansNow, you can extend the value of your Zoom meetings out to 100,000 people concurrently with Q&A on the Inferno Platform, amplify your video experiences...

NASHVILLE, Tenn., March 24, 2020 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW) and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow, announced that they have entered into an exclusive agreement with Doxy.me, a full-service telemedicine solution. This agreement will provide all ImprimisRx ophthalmology, optometry, and wellness practices with the Clinic level Doxy.me telemedicine solution at no charge. Doxy.me is one of the largest, yet simplest, telemedicine software solutions in the world, providing video, audio and text through which patients and healthcare providers can seamlessly communicate remotely.Mark L. Baum, CEO of Harrow Health, said, “ImprimisRx was founded on the principles of innovation and always putting patients...

Today, The Drilling Company of 1972 A/S (“Maersk Drilling”) announces that it has received a notification from Tullow Ghana Ltd. (“Tullow”) of early termination for convenience of the drilling contract for the drillship Maersk Venturer.Since February 2018, Maersk Venturer has worked for Tullow offshore Ghana with an expected end of contract in February 2022. The rig is now expected to end the contract in June 2020. As a consequence of the termination, Maersk Drilling’s revenue contract backlog is reduced by USD 175m covering the period from the end of the contract to February 2022.Subject to commercial prospects, Maersk Drilling will take measures to reduce Maersk Venturer’s operating costs following the end of the contract.Maersk Drilling maintains the profitability guidance for 2020 of EBITDA before special items of USD 325-375m as...

      Der er den 23. marts 2020 konstateret, at der er fejl i beregningen af indre værdi i Investeringsforeningen PFA Invest, afdeling Danske Aktier, der har medført at afdelingens indre værdi i perioder har afveget med mere end 0,5 %.Nedenfor er en oversigt over afvigelserne til indre værdi med den relevante periode angivet. Udover denne meddelelse, er der foretaget underretning til foreningens depotselskab, samt børsmæglerforeningens medlemmer, med henblik på kontakt til de berørte kunder for en korrektion af indgåede handler.Med venlig hilsenPFA Asset Management A/S

TORONTO, March 24, 2020 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “Lung Endothelial Binding Agents And Methods Of Use” to protect new drug candidates that reduce lung inflammation.This provisional patent application protects compositions and the method of use for novel drug molecules designed to inhibit lung inflammation in the context of bacterial and viral pneumonia. The compositions target distinct pathways independent from Arch Biopartners’ lead drug candidate Metablok (LSALT peptide), providing additional capability to reduce lung inflammation...

Fourth Quarter Total Adjusted Net Revenue Increases 7% to RUB 6,253 Million and Adjusted Net Profit Increases 15% to RUB 1,168 Million or RUB 18.74 per diluted shareFull-Year 2019 Total Adjusted Net Revenue Increases 18% to RUB 23,176 Million and Adjusted Net Profit Increases 61% to RUB 6,679 Million or RUB 107.27 per diluted shareQIWI gives 2020 GuidanceBoard of Directors Approves Dividend Payout Ratio for 2020NICOSIA, Cyprus, March 24, 2020 (GLOBE NEWSWIRE) — QIWI plc (NASDAQ: QIWI) (MOEX: QIWI) (“QIWI” or the “Company”) today announced results for the fourth quarter and full year ended December 31, 2019.Fourth Quarter 2019 Operating and Financial Highlights

Company announcement no 5-2020Annual report for the period January 1 to December 31, 2019 as approved by the Board of Directors.Highlights